Exceptional SCLC Survivors: 5-Year Median Survival Exceptional SCLC Survivors: 5-Year Median Survival
Longer-term survival of patients with extensive small cell lung cancer (SCLC) is associated with comprehensive cisplatin chemotherapy with additional chest and cranial radiation, suggest researchers.Medscape Medical News
Source: Medscape Hematology-Oncology Headlines - Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
More News: Cancer | Cancer & Oncology | Chemotherapy | Hematology | Lung Cancer | Small Cell Lung Cancer